BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 20371677)

  • 1. Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer.
    Saito K; Kawakami K; Matsumoto I; Oda M; Watanabe G; Minamoto T
    Clin Cancer Res; 2010 Apr; 16(8):2418-26. PubMed ID: 20371677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival.
    Brabender J; Usadel H; Danenberg KD; Metzger R; Schneider PM; Lord RV; Wickramasinghe K; Lum CE; Park J; Salonga D; Singer J; Sidransky D; Hölscher AH; Meltzer SJ; Danenberg PV
    Oncogene; 2001 Jun; 20(27):3528-32. PubMed ID: 11429699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA methylation markers and early recurrence in stage I lung cancer.
    Brock MV; Hooker CM; Ota-Machida E; Han Y; Guo M; Ames S; Glöckner S; Piantadosi S; Gabrielson E; Pridham G; Pelosky K; Belinsky SA; Yang SC; Baylin SB; Herman JG
    N Engl J Med; 2008 Mar; 358(11):1118-28. PubMed ID: 18337602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer.
    Chang YS; Wang L; Liu D; Mao L; Hong WK; Khuri FR; Lee HY
    Clin Cancer Res; 2002 Dec; 8(12):3669-75. PubMed ID: 12473575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer.
    Hsu HS; Wen CK; Tang YA; Lin RK; Li WY; Hsu WH; Wang YC
    Clin Cancer Res; 2005 Aug; 11(15):5410-6. PubMed ID: 16061855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features.
    Kim DS; Kim MJ; Lee JY; Kim YZ; Kim EJ; Park JY
    Cancer; 2007 Dec; 110(12):2785-92. PubMed ID: 17960794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma.
    Kim JS; Han J; Shim YM; Park J; Kim DH
    Cancer; 2005 Nov; 104(9):1825-33. PubMed ID: 16177988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer.
    Kikuchi S; Yamada D; Fukami T; Masuda M; Sakurai-Yageta M; Williams YN; Maruyama T; Asamura H; Matsuno Y; Onizuka M; Murakami Y
    Clin Cancer Res; 2005 Apr; 11(8):2954-61. PubMed ID: 15837747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of p16(INK4a) hypermethylation in non-small cell lung cancer is evident by quantitative DNA methylation analysis.
    Ota N; Kawakami K; Okuda T; Takehara A; Hiranuma C; Oyama K; Ota Y; Oda M; Watanabe G
    Anticancer Res; 2006; 26(5B):3729-32. PubMed ID: 17094392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypermethylation of the TSLC1/IGSF4 promoter is associated with tobacco smoking and a poor prognosis in primary nonsmall cell lung carcinoma.
    Kikuchi S; Yamada D; Fukami T; Maruyama T; Ito A; Asamura H; Matsuno Y; Onizuka M; Murakami Y
    Cancer; 2006 Apr; 106(8):1751-8. PubMed ID: 16534787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma.
    Maruyama R; Sugio K; Yoshino I; Maehara Y; Gazdar AF
    Cancer; 2004 Apr; 100(7):1472-7. PubMed ID: 15042681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome.
    Brabender J; Usadel H; Metzger R; Schneider PM; Park J; Salonga D; Tsao-Wei DD; Groshen S; Lord RV; Takebe N; Schneider S; Hölscher AH; Danenberg KD; Danenberg PV
    Clin Cancer Res; 2003 Jan; 9(1):223-7. PubMed ID: 12538473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer.
    Wang J; Lee JJ; Wang L; Liu DD; Lu C; Fan YH; Hong WK; Mao L
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6119-25. PubMed ID: 15447998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypermethylation of E-cadherin gene is frequent and independent of p16INK4A methylation in non-small cell lung cancer: potential prognostic implication.
    Shimamoto T; Ohyashiki JH; Hirano T; Kato H; Ohyashiki K
    Oncol Rep; 2004 Aug; 12(2):389-95. PubMed ID: 15254707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer.
    Kim DH; Kim JS; Ji YI; Shim YM; Kim H; Han J; Park J
    Cancer Res; 2003 Jul; 63(13):3743-6. PubMed ID: 12839968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of prognostic significance of serum DNA methylation of DAPK, MGMT, and GSTPI in patients with non-small cell lung cancer.
    Hoffmann AC; Kaifi JT; Vallböhmer D; Yekebas E; Grimminger P; Leers JM; Izbicki JR; Hölscher AH; Schneider PM; Metzger R; Brabender J
    J Surg Oncol; 2009 Oct; 100(5):414-7. PubMed ID: 19653236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer.
    Zhang Y; Miao Y; Yi J; Wang R; Chen L
    Clin Lung Cancer; 2010 Jul; 11(4):264-70. PubMed ID: 20630829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients.
    Ulivi P; Zoli W; Calistri D; Fabbri F; Tesei A; Rosetti M; Mengozzi M; Amadori D
    J Cell Physiol; 2006 Mar; 206(3):611-5. PubMed ID: 16222700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features.
    Cho NY; Kim BH; Choi M; Yoo EJ; Moon KC; Cho YM; Kim D; Kang GH
    J Pathol; 2007 Feb; 211(3):269-77. PubMed ID: 17139617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.